Logo
Phone Icon
1-855-4-MEDINFO (855-463-3463)

1-855-4-MEDINFO (855-463-3463)

[email protected]
Back

INCA33890

INCA33890 is an investigational TGFβR2×PD-1-directed bispecific antibody.1a

Recruiting & Ongoing Clinical Studies

Condition
Study Title
Phase
Resources & Links
Colorectal cancer
A Randomized, Double-Blind Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
3
NCT07284849 View Resource
Solid tumors
An Open-Label, Multicenter Study in Participants With Advanced or Metastatic Solid Tumors
1
NCT05836324 View Resource

Transforming Growth Factor β Receptor 2 & Programmed Cell Death Protein 1 (TGFβR2×PD-1)

INCA33890

TGFβ is a multifunctional cytokine expressed in most tissues and cell types.2 The TGFβ pathway is activated by TGFβR1 and TGFβR2 binding to TGFβ1/2/3 to form a tetrameric complex.3

TGFβ signaling suppresses immune cell-mediated antitumor immunity and predicts poor response to PD-(L)1 targeted therapy.4

  • Blockade of TGFβ signaling in T cells enhanced tumor antigen-specific T-cell responses and inhibited tumor development.5
  • However, initial therapeutic approaches targeting the TGFβ pathway have been hampered by poor specificity and toxicity issues.3
  • Cell-specific targeting may improve clinical activity and reduce adverse events associated with systemic inhibition of TGFβ.6

aIn collaboration with Merus.

References: 1. Wang LCS, et al. AACR 2023. Poster 2936. 2. Deng Z, et al. Signal Transduct Target Ther. 2024;9:61. 3. Ali S, et al. Eur J Pharmacol. 2023:947:175678. 4. Mariathasan S, et al. Nature. 2018;554:544-548. 5. Donkor MK, et al. Immunity. 2011;35:123-34. 6. Gulley JL, et al. Mol Oncol. 2022;16:2117-2134.

Top